Agilent Introduces Preclinical MRI System
Product News May 09, 2012
Agilent Technologies Inc. has launched the nScope eMRI preclinical imaging system at the annual meeting of the International Society for Magnetic Resonance in Medicine. With its new nScope eMRI system, Agilent is transforming how researchers view disease.
The latest addition to Agilent’s MRI product line, the nScope eMRI system features an improved interface that enables unparalleled ease of use.
Optimized packages uniquely align with specific user requirements, and a redesigned workflow ensures simple and ergonomic operation.
“The imaging protocols are a valuable step toward the ease of use of a clinical system while retaining the full flexibility of an experimental system,” said Ian Marshall, a professor at the School of Clinical Sciences at the University of Edinburgh.
Marshall continued, “They will be particularly useful to new users who wish to generate biomedical results without being bogged down in technical detail.”
The nScope eMRI system is focused on researchers who need the valuable information that can be gleaned from MRI.
The system has been designed with the explicit goal of making the imaging aspect of their research as simple as possible.
“We are very pleased with how we have been able to take the former Varian MRI product and shape it into a basic tool for the biological research community,” said Regina Schuck, vice president for Agilent Research Products.
Schuck continued, “This new product is a key step forward in Agilent’s commitment to being a leader in the field of life sciences.”
All pre-clinical researchers will enjoy the ease-of-use evolution that includes integrated specimen life support, precise laser-guided sample positioning, and ergonomic workflow.
The MRI software has improved image viewing tools, as well as a collection of validated protocols appropriate for routine imaging experiments for brain and heart.
For the advanced users, there are new CSI tools designed for use with DNP experiments enabling customers to push their 13C research forward.